Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Biotech ETFs Gaining on Progress in Coronavirus Treatment
11:04pm, Tuesday, 21'st Apr 2020
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
12:00pm, Tuesday, 21'st Apr 2020
NEW YORK and CLEVELAND, April 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian.
NEW YORK, April 17, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
12:35pm, Wednesday, 15'th Apr 2020
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
12:35pm, Wednesday, 15'th Apr 2020
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
01:53pm, Tuesday, 14'th Apr 2020
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
12:37pm, Tuesday, 14'th Apr 2020
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Update: Mesoblast (ASX:MSB) Stock Gained 57% In The Last Year
11:46pm, Monday, 13'th Apr 2020
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors...
More than 20 Companies Are Working on Coronavirus Treatments or Vaccines
06:27pm, Friday, 10'th Apr 2020
COVID-19 cases make up over 1,617,204 today, with 466,299 of them in the U.S. Over 20 companies are working on coronavirus vaccine or drugs.
Pluristem Therapeutics Shares Jump on Covid-19 Study Results
03:38pm, Friday, 10'th Apr 2020
The Israeli company reported its placenta-based treatment seemed to reduce complications in a small study Continue reading...
NRZ, RIG among premarket gainers
01:17pm, Thursday, 09'th Apr 2020
Tiziana Life Sciences PLC (NASDAQ:TLSA) +68% on inhalable treatment for COVID-19.Nautilus (NYSE:NLS) +43% after stay-at-home effect on sales.Exantas Capital (NYSE:XAN) +37%.Transocean (NYSE:RIG) +30
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 8) * Keros Therapeutics Inc (NASDAQ: KROS) (went public
MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
11:15pm, Wednesday, 08'th Apr 2020
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled
Mesoblast's COVID-19 Foray, And Other News: The Good, Bad And Ugly Of Biopharma
09:16pm, Wednesday, 08'th Apr 2020
Mesoblast was up on an IND approval targeting COVID-19. Crinetics announced positive trial data. Bellerophon announced earnings and program updates.
84 Biggest Movers From Yesterday
09:47am, Tuesday, 07'th Apr 2020
Gainers
Immunomedics, Inc. (NASDAQ: IMMU) shares jumped 99.8% to close at $18.78 on Monday after the company said it would stop its Ascent Study due to compelling evidence of...
